Pictet Asset Management Ltd. purchased a new position in Dermira, Inc. (NASDAQ:DERM) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 83,200 shares of the biopharmaceutical company’s stock, valued at approximately $2,246,000. Pictet Asset Management Ltd. owned about 0.20% of Dermira as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of DERM. BNP Paribas Arbitrage SA boosted its position in shares of Dermira by 2,220.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 3,975 shares during the last quarter. SG Americas Securities LLC raised its stake in Dermira by 66.8% during the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 2,203 shares during the period. KCG Holdings Inc. acquired a new stake in Dermira during the 1st quarter worth $215,000. Legal & General Group Plc raised its stake in Dermira by 16.3% during the 1st quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 963 shares during the period. Finally, Ardsley Advisory Partners acquired a new stake in Dermira during the 2nd quarter worth $291,000. Institutional investors and hedge funds own 98.09% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.truebluetribune.com/2017/11/14/pictet-asset-management-ltd-invests-2-25-million-in-dermira-inc-derm.html.
Shares of Dermira, Inc. (DERM) opened at $24.79 on Tuesday. Dermira, Inc. has a 12 month low of $21.35 and a 12 month high of $38.75. The company has a debt-to-equity ratio of 1.40, a quick ratio of 4.68 and a current ratio of 4.68.
In other Dermira news, CEO Thomas G. Wiggans sold 9,500 shares of Dermira stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $27.51, for a total value of $261,345.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Eugene A. Bauer sold 7,500 shares of Dermira stock in a transaction dated Wednesday, October 11th. The shares were sold at an average price of $30.04, for a total value of $225,300.00. The disclosure for this sale can be found here. Insiders sold a total of 29,400 shares of company stock worth $822,553 in the last three months. Company insiders own 13.30% of the company’s stock.
Several analysts recently commented on DERM shares. Zacks Investment Research downgraded Dermira from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $45.00 price objective on shares of Dermira in a research note on Tuesday, September 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $46.00 price objective on shares of Dermira in a research note on Sunday, September 17th. BidaskClub downgraded Dermira from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 10th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $41.00 price objective (down previously from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. Five investment analysts have rated the stock with a sell rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $43.33.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Want to see what other hedge funds are holding DERM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dermira, Inc. (NASDAQ:DERM).
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.